Splose Raises $46 Million Series A to Expand AI Tools in UK Allied Health Market
Adelaide-based allied health software platform Splose has secured $46 million in Series A funding, led by Spectrum Equity. The company aims to grow in the UK and enhance AI capabilities for allied health practitioners. Splose's valuation is reportedly above $100 million, with software used by over 20,000 practitioners across Australia, New Zealand, and the UK. The funding will accelerate product development and integration of AI tools.
Theia Market Signal Identification - AI Assisted
Splose, an allied health software platform from Adelaide, has raised $46 million in Series A funding, marking a record for South Australian SaaS businesses. Led by Spectrum Equity, with participation from Athletic Ventures, the new funding follows a $5 million round in 2025.
Splose's software serves over 20,000 practitioners and has experienced over 100% year-on-year growth. The company is focused on expanding in the UK, where it has seen a 300% growth since its entry 18 months ago. The capital will enhance product development and AI integration across its platform, offering features like transcription and workflow automation.
Comments